JPRN-UMIN000006009已完成未知
A feasibility study of docetaxel + cisplatin + capecitabine (DCX) therapy for unresectable advanced gastric cancer - A feasibility study of docetaxel + cisplatin + capecitabine (DCX) therapy for unresectable advanced gastric cancer
Department of Gastroenterology, Nagoya University Graduate School of Medicine0 个研究点目标入组 6 人开始时间: 2011年7月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) HER2 IHC 3+, or IHC 2 and FISH+ 2) Uncontrolled diabetes 3) Uncontrolled hypertension 4) Unstable angina pectoris, or a history of myocardial infarction within six months 5) Chronic lung disease: interstitial pneumonia, pulmonary fibrosis, or severe emphysema 6) Synchronous cancers 7) Systemic infection requiring treatment 8) Fever above 38 degree Celsius 9) A possibility of pregnancy or during pregnancy, or lactating women 10) Psychosis or psychotic symptoms 11) Continuous systemic administration of steroids (oral or intravenous)
研究者
相似试验
招募中
不适用
Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.gastric cancerJPRN-UMIN000005984Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)20
未知
2 期
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
已完成
2 期
Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small sell lung carcinoma (NSCLC)on-small sell lung carcinoma (NSCLC)JPRN-C000000310The Tokyo cooperative oncology group150
已完成
2 期
Efficacy and feasibility study of docetaxel + capecitabine followed by FEC neoadjuvant therapy for hormone receptor positive and HER2 negative breast cancerBreast cancerJPRN-UMIN000013274Department of Surgical Oncology, Osaka City University Graduate School of Medicine20
已完成
不适用
Phase II trial of docetaxel+cisplatin+capecitabine (DCX) therapy for unresectable or recurrent HER2-negative gastric cancerGastric cancerJPRN-UMIN000026722Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital35